On October 20, 2017, the U.S. Food and Drug Administration (FDA) licensed Shingrix® for adults aged 50 years and older to prevent shingles.
On October 25, 2017, the Advisory Committee on Immunization Practices (ACIP) voted that Shingrix® is:
- recommended for healthy adults aged 50 years and older to prevent shingles and related complications
- recommended for adults who previously received the current shingles vaccine (Zostavax®) to prevent shingles and related complications
- the preferred vaccine for preventing shingles and related complications
Once approved by the CDC director, these ACIP recommendations will be published in the Morbidity and Mortality Weekly Report. At that time, the recommendations will become official policy.